期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 21, 期 41, 页码 11621-11635出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v21.i41.11621
关键词
Metastatic gastric cancer; Second-line chemotherapy; Targeted therapy; Taxane; Irinotecan; Ramucirumab
Gastric cancer remains one among the leading causes of cancer-related deaths, regardless of its decreasing incidence and newly available treatment options. Most patients present at an advanced stage and are treated with upfront systemic chemotherapy. Those patients receiving first-line therapy may initially respond to treatment, but many of them relapse over time. In such condition, second-line treatment for disease progression remains the only available option. Although there exists no standard approach in the second-line setting, several phase. trials have shown modest survival benefit in patients receiving irinotecan, taxane and ramucirumab over the best supportive care or active agents. This review analyzes the currently available treatment regimens and future directions of research in the second-line setting for metastatic gastric cancer with the best available evidence. Additionally, the prognostic factors that influence patient survival in those receiving second-line therapy are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据